Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia

References

• Vallejo-VazAJRobertsonMCatapanoALLow-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-UpCirculation2017136201878189128877913
   PubMed Web of Science ®Google Scholar
• ReinerŽStatins in the primary prevention of cardiovascular diseaseNat Rev Cardiol201310845346423736519
   PubMed Web of Science ®Google Scholar
• KoskinasKCSiontisGCMPiccoloREffect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trialsEur Heart J201839141172118029069377
   PubMed Web of Science ®Google Scholar
• GrundySMPromise of low-density lipoprotein-lowering therapy for primary and secondary preventionCirculation2008117456957318227397
   PubMed Web of Science ®Google Scholar
• CohenJDBrintonEAItoMKJacobsonTAUnderstanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin usersJ Clin Lipidol20126320821522658145
   PubMed Web of Science ®Google Scholar
• ReinerZResistance and intolerance to statinsNutr Metab Cardiovasc Dis201424101057106624996502
   PubMed Web of Science ®Google Scholar
• RidkerPMMoraSRoseLJUPITER Trial Study GroupPercent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agentsEur Heart J201637171373137926916794
   PubMed Web of Science ®Google Scholar
• WongNDChuangJWongKPhamANeffDMarrettEResidual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009–2010)Am J Cardiol2013112337337923642513
   PubMed Web of Science ®Google Scholar
• PageMMWattsGFPCSK9 inhibitors – mechanisms of actionAust Prescr201639516416727789927
   PubMed Web of Science ®Google Scholar
• ReinerŽPCSK9 inhibitors – past, present and futureExpert Opin Drug Metab Toxicol201511101517152126329686
   PubMed Web of Science ®Google Scholar
• ReinerŽPCSK9 inhibitors in clinical practice: Expectations and realityAtherosclerosis201827018718829366497
   PubMed Web of Science ®Google Scholar
• SabatineMSGiuglianoRPKeechACFOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseN Engl J Med2017376181713172228304224
   PubMed Web of Science ®Google Scholar
• LardizabalJADeedwaniaPCBenefits of statin therapy and compliance in high risk cardiovascular patientsVasc Health Risk Manag2010684385320957130
   PubMedGoogle Scholar
• FordIMurrayHPackardCJShepherdJMacfarlanePWCobbeSMWest of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention StudyN Engl J Med2007357151477148617928595
   PubMed Web of Science ®Google Scholar
• HoPMMagidDJShetterlySMMedication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery diseaseAm Heart J2008155477277918371492
   PubMed Web of Science ®Google Scholar
• MillerLGHaysRDAdherence to combination antiretroviral therapy: synthesis of the literature and clinical implicationsAIDS Read200010317718510758022
   PubMedGoogle Scholar
• KolandaiveluKLeidenBBO’GaraPTBhattDLNon-adherence to cardiovascular medicationsEur Heart J201435463267327625265973
   PubMed Web of Science ®Google Scholar
• BarolettiSdell’orfanoHMedication adherence in cardiovascular diseaseCirculation2010121121455145820351303
   PubMed Web of Science ®Google Scholar
• NunesJPStatins in primary prevention: impact on mortality. A meta-analysis studyMinerva Cardioangiol201765553153828249380
   PubMed Web of Science ®Google Scholar
• RodriguezFMaronDJKnowlesJWViraniSSLinSHeidenreichPAAssociation Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular DiseaseJAMA Cardiol201721475427829091
   PubMed Web of Science ®Google Scholar
• BatesTRConnaughtonVMWattsGFNon-adherence to statin therapy: a major challenge for preventive cardiologyExpert Opin Pharmacother200910182973298519954271
   PubMed Web of Science ®Google Scholar
• WoutersHvan DijkLGeersHCUnderstanding Statin Non-Adherence: Knowing Which Perceptions and Experiences Matter to Different PatientsPLoS One2016111e014627226808151
   PubMed Web of Science ®Google Scholar
• GragnanoFConcilioCCesaroAP1513Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapyEur Heart J201738suppl_1P1513
   Google Scholar
• TorresPRPortillaAJGonzalezMO5PSQ-025 Real-world effectiveness and safety of evolocumab and alirocumabEur J Hosp Pharm201825A176
   Google Scholar
• SaborowskiMDölleMMannsMPLeitolfHZenderSLipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohortCardiol J2018251324129168543
   PubMed Web of Science ®Google Scholar
• GraesdalADybvigAReal-life PCSK9 experience: Efficacy, compliance and side effects after one year treatment in familial hypercholesterolemia patientsJ Am Coll Cardiol20187111A1754
   Web of Science ®Google Scholar
• DentRJoshiRStephen DjedjosCEvolocumab lowers LDL-C safely and effectively when self-administered in the at-home settingSpringerplus2016530027066336
   PubMedGoogle Scholar
• BoccaraFDentRRuilopeLValensiPPractical considerations for the use of subcutaneous treatment in the management of DyslipidaemiaAdv Ther20173481876189628717862
   PubMed Web of Science ®Google Scholar
• KaziDSMoranAECoxsonPGCost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular DiseaseJAMA2016316774375327533159
   PubMed Web of Science ®Google Scholar
• ArrietaAHongJCKheraRViraniSSKrumholzHMNasirKUpdated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER TrialJAMA Cardiol20172121369137429049467
   PubMed Web of Science ®Google Scholar
• KosmasCEDejesusEMorceloRGarciaFMontanPDGuzmanELipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapyDrugs Context2017621251129209403
   PubMedGoogle Scholar
• National Institute for Health and Care ExcellenceEvolocumab for Treating Primary Hypercholesterolaemia and Mixed DyslipidaemiaLondonNational Institute for Health and Care Excellence2016
   Google Scholar
• KormanMWisløffTModelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian settingEur Heart J Cardiovasc Pharmacother201841152228444187
   PubMed Web of Science ®Google Scholar
• LeeTCKaouacheMGroverSAEvaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysisCMAJ Open201862E162E167
   Google Scholar
• BaumSJTothPPUnderbergJAJellingerPRossJWilemonKPCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payersClin Cardiol201740424325428328015
   PubMed Web of Science ®Google Scholar
• KaziDSPenkoJOllendorfDACoxsonPGBibbins-DomingoKEffect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 InhibitorsAnn Intern Med20181681289689829610832
   PubMed Web of Science ®Google Scholar
• KosmasCEMuñoz EstrellaASourlasAInclisiran: A New Promising Agent in the Management of HypercholesterolemiaDiseases20186363
   PubMedGoogle Scholar